GlassScriptPhysician profile
Dennis Dobard
NPI 1063554038
$10,159.66
in general payments reported to CMS, 2019-2025
26 companies · $2,812 in 2025
The $2,812 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $409 · 2021: $722 · 2022: $1,191 · 2023: $2,279 · 2024: $2,438 · 2025: $2,812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,440 · Education: $89.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,439.60 |
| Education | $89.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,421.00 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $1,194.38 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $1,029.61 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Supernus Pharmaceuticals, INC. | $865.16 | 2023-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $829.76 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $761.85 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $756.08 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $558.27 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $510.83 | 2020-2025 | Caplyta |
| Abbvie INC. | $397.65 | 2022-2025 | Vraylar |
| E.R. Squibb & Sons, L.L.C. | $338.50 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $315.88 | 2019-2025 | Rexulti |
| Corium, LLC | $218.09 | 2023-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $210.81 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $161.01 | 2020-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $123.09 | 2020-2022 | |
| Indivior INC. | $113.22 | 2023-2024 | Perseris |
| Avanir Pharmaceuticals, INC. | $72.13 | 2022 | |
| Ironshore Pharmaceuticals INC. | $61.07 | 2023-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $52.54 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $51.52 | 2023-2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $36.88 | 2025 | Jornay Pm |
| Tris Pharma INC | $23.82 | 2025 | Dyanavel Xr |
| Sun Pharmaceutical Industries INC. | $22.61 | 2021 | |
| Avion Pharmaceuticals | $21.73 | 2023 | Methylphenidate Hydrochloride |
| Allergan, INC. | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Dobard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.